ACT on MASH: A Multi-country, Cross-sectional Quantitative Study Exploring Awareness, Understanding, and Perceptions of the Relation Between Cardiorenal Metabolic Conditions and MASLD/MASH Among Healthcare Providers, People With MASLD/MASH, and At-risk Population
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 1,330
- 试验地点
- 5
- 主要终点
- Description of awareness, understanding, and perception of MASLD/MASH, comorbidities, and risk factors
研究概览
简要总结
The purpose of this study is to collect information for scientific research and to better understand awareness and to understand overall risk awareness, diagnoses and treatment related to liver related diseases. The study aims to collect valid responses through online questionnaires from the participants. This study is a survey-based study without collection of laboratory data. It will take the participant 25 minutes to complete the survey. The study is not related to any specific treatment options or pharmaceutical product.
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Cross Sectional
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •HCP inclusion criteria
- •Informed consent obtained before any study-related activities (study-related activities are any procedure related to recording of data according to the protocol).
- •Male or female, age above or equal to 18 years at the time of signing informed consent.
- •Licensed to practice medicine in one of the countries of interest: United States, Canada, France, Germany, Japan
- •Must be a practicing endocrinologist, hepatologist, cardiologist, obesity specialist, primary care physician, radiologist, nurse practitioner or physician assistant (NP/PA US only)
- •Must be at least "somewhat familiar" (as opposed to "not at all familiar) with Metabolic dysfunction-associated steatohepatitis (MASH) (do not need to be currently treating people with MASH)
- •Must have at least 2 years in practice
- •Must spend at least 50 percentage of their time in patient care
- •Diagnosed patient inclusion criteria
- •Informed consent obtained before any study-related activities (study-related activities are any procedure related to recording of data according to the protocol).
- •Male or female, age above or equal to 18 years at the time of signing informed consent.
- •Diagnosis of MASH or Metabolic Associated Steatotic Liver Disease (MASLD) within past 24 months
- •Live in one of the countries of interest: United States, Canada, France, Germany, Japan
- •Have at least one comorbid condition: obesity, pre-diabetes, type 2 diabetes (T2D), metabolic syndrome, dyslipidaemia, hypertension, cardiovascular disease, chronic kidney disease
- •At risk patient inclusion criteria
- •Informed consent obtained before any study-related activities (study-related activities are any procedure related to recording of data according to the protocol).
- •Male or female, age above or equal to 18 years at the time of signing informed consent.
- •Live in one of the countries of interest: United States, Canada, France, Germany, Japan
- •Must have one or more risk factors associated with MASH [obesity, pre-diabetes, type 2 diabetes (T2D), metabolic syndrome, dyslipidaemia, hypertension, cardiovascular disease, chronic kidney disease], be diagnosed with steatosis (incidental finding) or have a blood test that shows raised liver enzymes.
排除标准
- •Previous participation in this study. Participation is defined as having given informed consent in this study
- •Mental incapacity, unwillingness or language barriers precluding adequate understanding or cooperation
研究组 & 干预措施
HCP Group
This group includes Health Care Practitioners (HCPs) who self-report to being at least somewhat familiar with Metabolic dysfunction-associated steatohepatitis (MASH)
干预措施: No treatment given (Other)
Patient Groups
This group includes patients diagnosed with Metabolic dysfunction-associated steatohepatitis (MASH), diagnosed with Metabolic Associated Steatotic Liver Disease (MASLD), or at risk for development/diagnosis of MASH
干预措施: No treatment given (Other)
结局指标
主要结局
Description of awareness, understanding, and perception of MASLD/MASH, comorbidities, and risk factors
时间窗: At the time of survey (Day 1)
Healthcare Provider (HCP) Quantitative Segment 7-point Likert scale 1 indicates very strongly disagree and 7 indicates very strongly agree
次要结局
未报告次要终点